Objective: To assess the effects of bisphosphonates (zoledronic acid injection) plus alendronate sodium on bone mineral density (BMD) and levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and insulin-like growth factor I (IGF-I) in patients with osteoporosis.
Materials And Methods: A total of 94 patients recruited from osteoporosis patients hospitalized in the period October 2021 to December 2022 were assigned to either a control group or an observation group using a random number table. The control group was treated with alendronate sodium alone, whereas the observation group received zoledronic acid injection in combination with alendronate sodium administered orally.
Results: Pre-treatment values for BMD, serum levels of IL-6, TNF-α, and IGF-I did not differ between the two groups (p > 0.05). However, post-treatment BMD measured at the femoral neck, in lumbar vertebrae, and Ward's triangle were increased, as was serum IGF-I level (p < 0.05). In contrast, in comparison with the control group, reductions were observed in serum IL-6 and TNF-α (p < 0.05). The incidence of adverse reactions such as nausea and vomiting, diarrhea, musculoskeletal pain, and hypocalcemia was significantly lower in the observation group (p < 0.05).
Conclusion: Zoledronic acid injection in combination with alendronate sodium increases the expression of IL-6, TNF-α, and IGF-I, suppresses bone resorption and promotes bone recovery in patients with osteoporosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5414/CP204706 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing bone health with bisphosphonate therapies in pediatric osteogenesis imperfecta: a network meta-analysis of randomized trials.
Arch Osteoporos
March 2025
Department of Orthopedics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, Tainan, 704, Taiwan.
Unlabelled: This study compares the efficacy of various bisphosphonate treatments for pediatric osteogenesis imperfecta (OI) in terms of lumbar spine areal bone mineral density (LS-aBMD), Z-scores, bone turnover markers (BTMs), fracture rates, and adverse events.
Purpose: The optimal bisphosphonate treatment for pediatric OI remains uncertain. This study aims to analyze the comparative effectiveness of different bisphosphonate therapies for children with OI.
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.
Osteoporos Int
March 2025
World Health Organization (WHO) Collaborating Center for Epidemiology of Musculoskeletal Health and Ageing, University of Liège, Liège, Belgium.
Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations. While randomized controlled trials (RCTs) demonstrate that PTH1 receptor agonists, teriparatide and abaloparatide, are effective at reducing fracture risk, real-world evidence (RWE) remains sparse. This study reviews and compares the anti-fracture efficacy of these agents, against each other and against other osteoporosis treatments using both RCTs and RWE.
View Article and Find Full Text PDFExploring the multifaceted impact of bisphosphonates on bone graft integration: transitioning from in vivo insights to clinical applications.
Arch Toxicol
March 2025
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Neurophysiology Unit, Chiang Mai University, Chiang Mai, 50200, Thailand.
Numerous researchers have explored the efficacy of the use of bisphosphonates, in particular alendronate and zoledronate, in bone graft integration. Mechanisms underlying the beneficial effects of bisphosphonates on bone graft integration have been previously investigated. Previous studies have demonstrated that both local and systemic applications of bisphosphonates in the integration of autogenous and allogenic bone grafts yield promising results in enhancing allograft and autograft outcomes.
View Article and Find Full Text PDFAnti-Osteoporosis and Bone Protective Effects of Resveratrol in Rats With Chronic Kidney Disease-Induced Osteoporosis.
Mol Nutr Food Res
March 2025
Department of Orthopaedics, Shanxi Bethune Hospital(Shanxi Academy of Medical Sciences), Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, Shanxi, China.
Chronic kidney disease (CKD)-induced osteoporosis is a new concept that implies CKD-related impaired bone quality. Resveratrol (RES) is a natural component, known for its anti-inflammatory and anti-osteoporotic effects. In the present study, we aimed to investigate the bone-protective and anti-osteoporotic effects of resveratrol in rats with chronic kidney disease-induced osteoporosis.
View Article and Find Full Text PDFOptimizing bone health in people living with HIV: insights from a network meta-analysis of randomized controlled trials.
EClinicalMedicine
March 2025
Department of Orthopedics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Background: With life expectancy for people living with HIV (PLWH) approaching that of the general population, age-related conditions like osteoporosis are increasingly common. Both HIV infection and long-term antiretroviral therapy (ART), particularly tenofovir disoproxil fumarate (TDF), are associated with early-onset osteoporosis. Bisphosphonates are commonly used for treatment, but the optimal strategy for improving bone health in PLWH remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!